AMD3100 Plus Pembrolizumab in Immune Checkpoint Blockade Refractory Head and Neck Squamous Cell Carcinoma
Status:
Withdrawn
Trial end date:
2019-10-11
Target enrollment:
Participant gender:
Summary
This research is studying the safety and effectiveness of AMD3100 and pembrolizumab in
participants with metastatic head and neck squamous cell carcinoma.